Myeloma Patients Europe (MPE)’s Post

Learn more about clinical trials in Europe for myeloma and AL amyloidosis patients by using our Navigator tool. You can find trials matching your criteria, from specific hospitals to disease stages. Explore the MPE Navigator now: https://lnkd.in/dDRHsv2Z #ClinicalTrials #Research #myeloma #ALAmyloidosis

🔍 Simplify your clinical trial search with the help of the MPE Navigator! 💡Unlock information and streamline your search for clinical trials with our platform. You can find trials tailored to your needs, from specific hospitals to disease stages and more. Visit the #MPENavigator to learn more and start your search today: https://lnkd.in/dDRHsv2Z #ClinicalTrials #myeloma #ALamyloidosis

🔬 Groundbreaking Clinical Trials Revealed: January 18, 2024 Highlights 🌟 Exciting news in the world of medicine! 🚀 On January 18th, several pivotal clinical trials were published, showcasing significant advancements in various fields. Here's a snapshot of some of the most impactful ones: COVID-19 Update 🦠: A new treatment shows promise in reducing symptom duration and viral load. A beacon of hope in our ongoing battle against COVID-19! #COVID19Research Alzheimer's Breakthrough 🧠: Innovative focused ultrasound therapy opens new doors in Alzheimer's treatment, showing changes in key biomarkers. A step closer to unraveling this mystery! #AlzheimersResearch Endometriosis Management 💪: Long-term relief from endometriosis-associated pain without heavy reliance on opioids. A huge win for women's health! #EndometriosisAwareness Advances in Breast Cancer Treatment 🎗️: Promising results in treating triple-negative breast cancer with combination therapy. Offering new hope to many! #BreastCancerAwareness Childhood Leukemia Success Stories 👶: Significant strides in reducing mortality in pediatric acute leukemia. A heartwarming development for our little warriors! #ChildhoodCancerAwareness Melanoma Treatment Evolution 🌞: mRNA technology making waves in melanoma treatment, showing improved recurrence-free survival rates. #MelanomaResearch These studies not only offer hope but also showcase the incredible strides being made in medical research. 💡 🔗 Want to dive deeper into these fascinating developments? Follow this link for more detailed information: https://lnkd.in/ddW_C-4b 👍 Don't forget to like, share, and follow for more updates and discussions on these groundbreaking studies. Let's keep the conversation going! #MedicalAdvancements #HealthcareInnovation

In December 2023, the FDA approved a groundbreaking gene-editing treatment for sickle cell disease. Now, the final results from the pivotal clinical trial are published in the New England Journal of Medicine. This study, coauthored by UIC’s Dr. Damiano Rondelli, reveals that the therapy significantly reduces painful symptoms. We're proud of Dr. Rondelli's contributions to this major medical milestone! Read the full story: https://loom.ly/l8F4_cM #UICAlumni #MedicalBreakthrough #UIC #UICProud #SickleCellDisease #UICHealth #UICResearch

Read our new article:  Kaye A D, Tassin J P, Upshaw W C, Patel C R, Hawkins A M, Burroughs C R, Bembenick K N, Mosieri C N, Ahmadzadeh S, Kaye A M, Shekoohi S, Varrassi G. December 03, 2024 Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review . Cureus 16(12): e75062. doi:10.7759/cureus.75062 Treatment for Systemic Lupus Erythematosus aims to reduce disease activity and maintain a state of low inflammation. In this regard, numerous treatments are used, such as hydroxychloroquine, glucocorticoids, and non-glucocorticoid immunosuppressants such as methotrexate. Related to these drugs resulting in significant adverse effects and being ineffective in controlling SLE symptoms in some patients, new biologic agents have been created in hopes of better treating SLE. This includes belimumab and anifrolumab, monoclonal antibodies directed against the cytokine, and type 1 interferon receptor, respectively. These agents are indicated in patients with SLE whose symptoms are inadequately controlled by standard therapy alone. Clinical trials have shown that these agents effectively reduce SLE symptoms as judged using standardized metrics of disease activity. These biological agents have also been shown to have generally mild side effects when taken by patients with SLE, making them safe for use. In addition to the above medications, new treatments are being developed for SLE patients, such as cenerimod, litifilimab, chimeric antigen receptor T cells, and DS-7011a (anti-toll-like receptor 7 monoclonal antibody). These new treatments have shown promise in clinical trials.     https://lnkd.in/gi-V_4FW

In the world of Duchenne research, collaboration and patient-centered approaches are crucial. Parent Project Muscular Dystrophy has embraced Clinical Trials Transformation Initiative (CTTI)’s Chevron Diagram to deepen the integration of patient voices into every phase of drug development. This approach has already led to significant progress, with seven patient preference studies completed, providing invaluable insights that are shaping the future of Duchenne disease. Learn more about PPMD’s successful collaboration with CTTI at https://bit.ly/PPMDcs.  

Intended for HCPs with an interest in GEA:   At Jazz, we believe all people, including those who live with complex conditions with limited options, deserve new therapeutic options to help improve outcomes.   The HERIZON-GEA-01 clinical trial seeks to explore the safety profile of our investigational treatment for people living with advanced/metastatic human epidermal growth factor receptor 2 (#HER2) positive gastroesophageal adenocarcinomas (#GEAs) and learn if it’s more efficacious than the current standard of care.   This trial is currently enrolling eligible patients, learn more: https://lnkd.in/g8RNyyQ8

Rethinking Clinical Trials in Oncology: Embracing Pragmatic Approaches Traditional randomized controlled trials (RCTs) in oncology often come with heavy monitoring, numerous assessments, and frequent follow-up visits. While essential for rigorous data, these demands can be overwhelming for participants, investigators, and sponsors alike. FDA believes that it's time to consider pragmatic clinical trials that mirror routine clinical practice more closely. These trials can streamline processes and focus on demonstrating efficacy with clear, straightforward endpoints like overall survival. For example, a critical question we should be asking is, "What is the median overall survival for patients with [specific type of cancer] treated with drug X versus drug Y?" By adopting pragmatic approaches, we can reduce the burden on all stakeholders while still obtaining valuable, real-world data. How is this possible? Let FDA know your two cents! It's its one-of-a-kind approach, #FDA wants you to share your ideas! This initiative allows the #innovators and key stakeholders in the field, to voice their opinion where it's heard the clearest! #Oncology #ClinicalTrials #HealthcareInnovation #PatientCentric #MedicalResearch Link to my two cents 👛: https://lnkd.in/ecgtkNJJ

Learn how biopharma and patient recruitment organizations are overcoming clinical trial recruitment challenges. In this webinar Sara Riordan MS, CGC, Genome Medical;  Bryan Federowicz, xCures; and Jill Pellegrino, AutoCruitment discuss solutions being implemented now to quickly identify and activate qualified clinical trial patients. Register: https://lnkd.in/gRg3gwC4

Have you watched any of our trial-overview videos, such as the STELLAR-305 study, designed to engage patients and empower them to start conversations with their care providers? Learn more here: https://buff.ly/4bKB08r #carcinoma #research #clinicaltrials #pharma #biotech #oncology CancerCare